Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay

US FDA user fee date for privately held company’s 351(k) application referencing Amgen’s Neupogen may have passed without word of a regulatory action; Amgen sued Adello in March alleging infringement of 17 patents covering the innovator product.